Intervet develops prototype for mass application avian influenza vaccine

14-Jun-2006

A biotech breakthrough achieved by Akzo Nobel's animal health business, Intervet, means that mass application of a dual vaccine against avian influenza and Newcastle Disease could be available in the near future. Together with scientists at the Friedrich-Loeffler-Institute (FLI) in Germany, Intervet has developed a prototype for a new generation vaccine offering protection against both infections which can be mass applied by spraying instead of injecting.

The new prototype vaccine consists of a safe live vaccine against Newcastle Disease (a condition affecting many bird species), which acts as a carrier for the haemagglutinin gene-the vital genetic material needed to build immunity against the avian influenza virus.

The new vaccine-which is scheduled to undergo field trials next year-can also be used on large numbers of birds as an efficient marker vaccine to help differentiate between infected and vaccinated birds.

Other news from the department science

Most read news

More news from our other portals

Discover the latest developments in battery technology!